{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:40:56Z","timestamp":1785548456953,"version":"3.56.0"},"reference-count":48,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The heterogeneous disease, breast cancer (BC), is a frequently detected cancer\ntoday, including hormone receptor-positive (HR+), human epidermal growth factor\nreceptor-2-positive (HER2+), and triple-negative (ER-, PR-, HER2-) BC. Advanced endocrine\ntherapies could improve about 85% HR+ BC patient survival. Still, 20% - 30%\nof cases of endocrine therapy resistance are observed. For all kinds of breast cancer,\ndrug resistance is a common and dangerous phenomenon, comprised of two types: de novo\nresistance and acquired resistance (prolonged exposure). According to recent works\nof literature, the PI3K\/AKT\/mTOR pathway has become an emerging target for overcoming\ndrug resistance in BC therapy due to its close association with tumour growth\nand resistance from current therapies. Activation of the PI3K\/AKT\/mTOR pathway was\nfound to promote multidrug resistance by elevating drugs\u2019 outflow. The first orally active\nPI3K inhibitor, Alpelisib (BYL-719) in fulvestrant combination, was approved for\ntreating HR+\/ HER2\u2212 metastatic BC. Therefore, utilizing PI3K\/mTOR\/AKT inhibitors\nin combination with currently available strategies could be an optimistic approach to\novercoming drug resistance and resensitizing drug-resistant tumor cells of BC. Here, in\nthis perspective, BC cancer therapies related to drug resistance, the involvement of\nPI3K\/AKT\/mTOR pathway in drug resistance and multi-drug resistance, and the role of\nPI3K\/AKT\/mTOR inhibitors in getting rid of drug resistance have been illuminated.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673327425240815065221","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T10:33:28Z","timestamp":1724322808000},"page":"1865-1873","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Perspective of PI3K\/AKT\/mTOR Pathway Inhibitors to Overcome Drug-resistance in Breast Cancer Therapy"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-1993","authenticated-orcid":true,"given":"Sudip Kumar","family":"Mandal","sequence":"first","affiliation":[{"name":"Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhannagar, Durgapur, 713212,\nWest Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Kumar","family":"Samanta","sequence":"additional","affiliation":[{"name":"Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Bidhannagar, Durgapur, 713212,\nWest Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"Arnold M.","year":"2022","unstructured":"Arnold M.; Morgan E.; Rumgay H.; Mafra A.; Singh D.; Laversanne M.; Vignat J.; Gralow J.R.; Cardoso F.; Siesling S.; Soerjomataram I.; Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast  2022,66,15-23","journal-title":"Breast"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1871520616666160502122724","volume":"17","author":"Nagini S.","year":"2017","unstructured":"Nagini S.; Breast cancer: Current molecular therapeutic targets and new players. Anti-Cancer Agents Med Chem  2017,17(2),152-163","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0305-7372(02)00036-1","volume":"28","author":"Clemons M.","year":"2002","unstructured":"Clemons M.; Danson S.; Howell A.; Tamoxifen (\u2018Nolvadex\u2019): a review. Cancer Treat Rev  2002,28(4),165-180","journal-title":"Cancer Treat Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.2174\/0929867329666221006110528","volume":"30","author":"Das A.","year":"2023","unstructured":"Das A.; Lavanya K.J.; Nandini ; Kaur K.; Jaitak V.; Effectiveness of selective estrogen receptor modulators in breast cancer therapy: an update. Curr Med Chem  2023,30(29),3287-3314","journal-title":"Curr Med Chem"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.clbc.2016.05.012","volume":"16","author":"Tang Y.","year":"2016","unstructured":"Tang Y.; Wang Y.; Kiani M.F.; Wang B.; Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer  2016,16(5),335-343","journal-title":"Clin Breast Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e88309","DOI":"10.1371\/journal.pone.0088309","volume":"9","author":"Wolf D.M.","year":"2014","unstructured":"Wolf D.M.; Lenburg M.E.; Yau C.; Boudreau A.; van \u2019t Veer L.J.; Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One  2014,9(2),e88309","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"Dong C.","year":"2021","unstructured":"Dong C.; Wu J.; Chen Y.; Nie J.; Chen C.; Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol  2021,12,628690","journal-title":"Front Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"x12","DOI":"10.1093\/annonc\/mdz381","volume":"30","author":"Verret B.","year":"2019","unstructured":"Verret B.; Cortes J.; Bachelot T.; Andre F.; Arnedos M.; Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol  2019,30,x12-x20","journal-title":"Ann Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","volume":"18","author":"Kathawala R.J.","year":"2015","unstructured":"Kathawala R.J.; Gupta P.; Ashby C.R.; Chen Z.S.; The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat  2015,18,1-17","journal-title":"Drug Resist Updat"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s40265-019-01161-6","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; Alpelisib: first global approval. Drugs  2019,79(11),1249-1253","journal-title":"Drugs"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10911-012-9264-2","volume":"17","author":"Cidado J.","year":"2012","unstructured":"Cidado J.; Park B.H.; Targeting the PI3K\/Akt\/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia  2012,17(3-4),205-216","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s10637-018-0563-3","volume":"36","author":"Liu S.","year":"2018","unstructured":"Liu S.; Tang Y.; Yan M.; Jiang W.; PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. Invest New Drugs  2018,36(5),763-772","journal-title":"Invest New Drugs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1080\/07391102.2023.2226751","volume":"42","author":"Allahyari M.","year":"2024","unstructured":"Allahyari M.; Motavalizadeh-Kakhky A.R.; Mehrzad J.; Zhiani R.; Chamani J.; Cellulose nanocrystals derived from chicory plant: an un-competitive inhibitor of aromatase in breast cancer cells via PI3K\/AKT\/mTOP signalling pathway. J Biomol Struct Dyn  2024,42(11),5575-5589","journal-title":"J Biomol Struct Dyn"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"Liu P.","year":"2009","unstructured":"Liu P.; Cheng H.; Roberts T.M.; Zhao J.J.; Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov  2009,8(8),627-644","journal-title":"Nat Rev Drug Discov"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"DeBerardinis R.J.","year":"2008","unstructured":"DeBerardinis R.J.; Lum J.J.; Hatzivassiliou G.; Thompson C.B.; The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab  2008,7(1),11-20","journal-title":"Cell Metab"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.18632\/oncotarget.13817","volume":"8","author":"Dai Y.","year":"2017","unstructured":"Dai Y.; Jin S.; Li X.; Wang D.; The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget  2017,8(1),1354-1368","journal-title":"Oncotarget"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"Manning B.D.","year":"2007","unstructured":"Manning B.D.; Cantley L.C.; AKT\/PKB signaling: navigating downstream. Cell  2007,129(7),1261-1274","journal-title":"Cell"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","volume":"59","author":"Murugan A.K.","year":"2019","unstructured":"Murugan A.K.; mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol  2019,59,92-111","journal-title":"Semin Cancer Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","volume":"7","author":"Dancey J.","year":"2010","unstructured":"Dancey J.; mTOR signaling and drug development in cancer. Nat Rev Clin Oncol  2010,7(4),209-219","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","volume":"118","author":"Carracedo A.","year":"2008","unstructured":"Carracedo A.; Ma L.; Teruya-Feldstein J.; Rojo F.; Salmena L.; Alimonti A.; Egia A.; Sasaki A.T.; Thomas G.; Kozma S.C.; Papa A.; Nardella C.; Cantley L.C.; Baselga J.; Pandolfi P.P.; Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest  2008,118(9),3065-3074","journal-title":"J Clin Invest"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","volume":"13","author":"Fritsch C.","year":"2014","unstructured":"Fritsch C.; Huang A.; Chatenay-Rivauday C.; Schnell C.; Reddy A.; Liu M.; Kauffmann A.; Guthy D.; Erdmann D.; De Pover A.; Furet P.; Gao H.; Ferretti S.; Wang Y.; Trappe J.; Brachmann S.M.; Maira S.M.; Wilson C.; Boehm M.; Garcia-Echeverria C.; Chene P.; Wiesmann M.; Cozens R.; Lehar J.; Schlegel R.; Caravatti G.; Hofmann F.; Sellers W.R.; Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther  2014,13(5),1117-1129","journal-title":"Mol Cancer Ther"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-319-91442-8_8","author":"Hasskarl J.","year":"2018","unstructured":"Hasskarl J.; Everolimus. Small Molecules in Oncology  2018,101-123","journal-title":"Small Molecules in Oncology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","volume":"84","author":"Shirley M.","year":"2024","unstructured":"Shirley M.; Capivasertib: First Approval. Drugs  2024,84(3),337-346","journal-title":"Drugs"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","volume":"30","author":"Singh S.","year":"2024","unstructured":"Singh S.; Bradford D.; Li X.; Mishra-Kalyani P.S.; Shen Y.L.; Wang L.; Zhao H.; Xiong Y.; Liu J.; Charlab R.; Kraft J.; Khasar S.; Miller C.P.; Rivera D.R.; Kluetz P.G.; Pazdur R.; Beaver J.A.; Singh H.; Donoghue M.; FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin Cancer Res  2024,30(1),23-28","journal-title":"Clin Cancer Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10549-014-3239-5","volume":"149","author":"Elster N.","year":"2015","unstructured":"Elster N.; Cremona M.; Morgan C.; Toomey S.; Carr A.; O\u2019Grady A.; Hennessy B.T.; Eustace A.J.; A preclinical evaluation of the PI3K alpha\/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib. Breast Cancer Res Treat  2015,149(2),373-383","journal-title":"Breast Cancer Res Treat"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s10637-014-0082-9","volume":"32","author":"Rodon J.","year":"2014","unstructured":"Rodon J.; Bra\u00f1a I.; Siu L.L.; De Jonge M.J.; Homji N.; Mills D.; Di Tomaso E.; Sarr C.; Trandafir L.; Massacesi C.; Eskens F.; Bendell J.C.; Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan- Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs  2014,32(4),670-681","journal-title":"Invest New Drugs"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2014.12.019","volume":"136","author":"Matulonis U.","year":"2015","unstructured":"Matulonis U.; Vergote I.; Backes F.; Martin L.P.; McMeekin S.; Birrer M.; Campana F.; Xu Y.; Egile C.; Ghamande S.; Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol  2015,136(2),246-253","journal-title":"Gynecol Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-13-2403","volume":"20","author":"Papadopoulos K.P.","year":"2014","unstructured":"Papadopoulos K.P.; Tabernero J.; Markman B.; Patnaik A.; Tolcher A.W.; Baselga J.; Shi W.; Egile C.; Ruiz-Soto R.; Laird A.D.; Miles D.; LoRusso P.M.; Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K\/mTOR inhibitor in patients with advanced solid tumors. Clin Cancer Res  2014,20(9),2445-2456","journal-title":"Clin Cancer Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10637-019-00776-6","volume":"38","author":"Shapiro G.I.","year":"2020","unstructured":"Shapiro G.I.; LoRusso P.; Kwak E.; Pandya S.; Rudin C.M.; Kurkjian C.; Cleary J.M.; Pilat M.J.; Jones S.; de Crespigny A.; Fredrickson J.; Musib L.; Yan Y.; Wongchenko M.; Hsieh H.J.; Gates M.R.; Chan I.T.; Bendell J.; Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. Invest New Drugs  2020,38(2),419-432","journal-title":"Invest New Drugs"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-18-0613","volume":"24","author":"Dickler M.N.","year":"2018","unstructured":"Dickler M.N.; Saura C.; Richards D.A.; Krop I.E.; Cervantes A.; Bedard P.L.; Patel M.R.; Pusztai L.; Oliveira M.; Cardenas A.K.; Cui N.; Wilson T.R.; Stout T.J.; Wei M.C.; Hsu J.Y.; Baselga J.; Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with her2-negative, hormone receptor\u2013positive advanced breast cancer. Clin Cancer Res  2018,24(18),4380-4387","journal-title":"Clin Cancer Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10637-020-00975-6","volume":"39","author":"Shapiro G.I.","year":"2021","unstructured":"Shapiro G.I.; LoRusso P.; Cho D.C.; Musib L.; Yan Y.; Wongchenko M.; Chang I.; Patel P.; Chan I.T.; Sanabria-Bohorquez S.; Meng R.D.; Bendell J.C.; A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors. Invest New Drugs  2021,39(1),163-174","journal-title":"Invest New Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","volume":"12","author":"Wise-Draper T.M.","year":"2017","unstructured":"Wise-Draper T.M.; Moorthy G.; Salkeni M.A.; Karim N.A.; Thomas H.E.; Mercer C.A.; Beg M.S.; O\u2019Gara S.; Olowokure O.; Fathallah H.; Kozma S.C.; Thomas G.; Rixe O.; Desai P.; Morris J.C.; A phase Ib study of the dual PI3K\/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol  2017,12(3),323-332","journal-title":"Target Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cpdd.613","volume":"8","author":"Patel C.G.","year":"2019","unstructured":"Patel C.G.; Rangachari L.; Patti M.; Griffin C.; Shou Y.; Venkatakrishnan K.; Characterizing the sources of pharmacokinetic variability for TAK-117 (Serabelisib), an investigational phosphoinositide 3-kinase alpha inhibitor: a clinical biopharmaceutics study to inform development strategy. Clin Pharmacol Drug Dev  2019,8(5),637-646","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","volume":"9","author":"Hirai H.","year":"2010","unstructured":"Hirai H.; Sootome H.; Nakatsuru Y.; Miyama K.; Taguchi S.; Tsujioka K.; Ueno Y.; Hatch H.; Majumder P.K.; Pan B.S.; Kotani H.; MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther  2010,9(7),1956-1967","journal-title":"Mol Cancer Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","volume":"14","author":"Rini B.I.","year":"2008","unstructured":"Rini B.I.; Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res  2008,14(5),1286-1290","journal-title":"Clin Cancer Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","volume":"10","author":"Rivera V.M.","year":"2011","unstructured":"Rivera V.M.; Squillace R.M.; Miller D.; Berk L.; Wardwell S.D.; Ning Y.; Pollock R.; Narasimhan N.I.; Iuliucci J.D.; Wang F.; Clackson T.; Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther  2011,10(6),1059-1071","journal-title":"Mol Cancer Ther"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41598-023-29425-y","volume":"13","author":"Rodriguez M.J.","year":"2023","unstructured":"Rodriguez M.J.; Perrone M.C.; Riggio M.; Palafox M.; Salinas V.; Elia A.; Salgueiro N.D.; Werbach A.E.; Marks M.P.; Kauffman M.A.; Vell\u00f3n L.; Serra V.; Novaro V.; Targeting mTOR to overcome resistance to hormone and CDK4\/6 inhibitors in ER-positive breast cancer models. Sci Rep  2023,13(1),2710","journal-title":"Sci Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-023-06895-2","volume":"199","author":"Fiascarelli A.","year":"2023","unstructured":"Fiascarelli A.; Merlino G.; Capano S.; Talucci S.; Bisignano D.; Bressan A.; Bellarosa D.; Carrisi C.; Paoli A.; Bigioni M.; Tunici P.; Irrissuto C.; Salerno M.; Arribas J.; de Stanchina E.; Scaltriti M.; Binaschi M.; Antitumor activity of the PI3K \u03b4-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer. Breast Cancer Res Treat  2023,199(1),13-23","journal-title":"Breast Cancer Res Treat"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"Jones R.H.","year":"2020","unstructured":"Jones R.H.; Casbard A.; Carucci M.; Cox C.; Butler R.; Alchami F.; Madden T.A.; Bale C.; Bezecny P.; Joffe J.; Moon S.; Twelves C.; Venkitaraman R.; Waters S.; Foxley A.; Howell S.J.; Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol  2020,21(3),345-357","journal-title":"Lancet Oncol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1158\/1078-0432.CCR-15-2764","volume":"23","author":"Hosford S.R.","year":"2017","unstructured":"Hosford S.R.; Dillon L.M.; Bouley S.J.; Rosati R.; Yang W.; Chen V.S.; Demidenko E.; Morra R.P.; Miller T.W.; Combined inhibition of both p110\u03b1 and p110\u03b2 isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer. Clin Cancer Res  2017,23(11),2795-2805","journal-title":"Clin Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10911-023-09539-9","volume":"28","author":"Amante R.J.","year":"2023","unstructured":"Amante R.J.; Jehanno C.; De Silva D.; Coissieux M.M.; Ackerknecht M.; Romanet V.; Sethi A.; Hamelin B.; Preca B.T.; Piscuoglio S.; Ng C.K.Y.; Mohseni M.; Bentires-Alj M.; PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer. J Mammary Gland Biol Neoplasia  2023,28(1),13","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e0116747","DOI":"10.1371\/journal.pone.0116747","volume":"10","author":"Tsou S.H.","year":"2015","unstructured":"Tsou S.H.; Chen T.M.; Hsiao H.T.; Chen Y.H.; A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS One  2015,10(1),e0116747","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.18632\/oncotarget.1952","volume":"5","author":"Sun C.","year":"2014","unstructured":"Sun C.; Zhang F.; Xiang T.; Chen Q.; Pandita T.K.; Huang Y.; Hu M.C.T.; Yang Q.; Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers. Oncotarget  2014,5(10),3375-3385","journal-title":"Oncotarget"},{"key":"ref=44","first-page":"E1","author":"Juric D.","year":"2018","unstructured":"Juric D.; Janku F.; Rodon J.; Burris H.A.; Mayer I.A.; Schuler M.; Seggewiss-Bernhard R.; Gil-Martin M.; Middleton M.R.; Baselga J.; Alpelisib (BYL719) plus Fulvestrant in PIK3CA-altered and PIK3CA wild-type ER+ advanced breast cancer. An open-label, phase 1b dose-escalation and expansion study. JAMA Oncol  2018,E1-E9","journal-title":"JAMA Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-16-1080","volume":"7","author":"Juric D.","year":"2017","unstructured":"Juric D.; Krop I.; Ramanathan R.K.; Wilson T.R.; Ware J.A.; Sanabria Bohorquez S.M.; Savage H.M.; Sampath D.; Salphati L.; Lin R.S.; Jin H.; Parmar H.; Hsu J.Y.; Von Hoff D.D.; Baselga J.; Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov  2017,7(7),704-715","journal-title":"Cancer Discov"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"Hudes G.","year":"2007","unstructured":"Hudes G.; Carducci M.; Tomczak P.; Dutcher J.; Figlin R.; Kapoor A.; Staroslawska E.; Sosman J.; McDermott D.; Bodrogi I.; Kovacevic Z.; Lesovoy V.; Schmidt-Wolf I.G.H.; Barbarash O.; Gokmen E.; O\u2019Toole T.; Lustgarten S.; Moore L.; Motzer R.J.; Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med  2007,356(22),2271-2281","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","volume":"70","author":"Chresta C.M.","year":"2010","unstructured":"Chresta C.M.; Davies B.R.; Hickson I.; Harding T.; Cosulich S.; Critchlow S.E.; Vincent J.P.; Ellston R.; Jones D.; Sini P.; James D.; Howard Z.; Dudley P.; Hughes G.; Smith L.; Maguire S.; Hummersone M.; Malagu K.; Menear K.; Jenkins R.; Jacobsen M.; Smith G.C.M.; Guichard S.; Pass M.; AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res  2010,70(1),288-298","journal-title":"Cancer Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","volume":"17","author":"Miller M.L.","year":"2018","unstructured":"Miller M.L.; Shizuka M.; Wilhelm A.; Salomon P.; Reid E.E.; Lanieri L.; Sikka S.; Maloney E.K.; Harvey L.; Qiu Q.; Archer K.E.; Bai C.; Vitharana D.; Harris L.; Singh R.; Ponte J.F.; Yoder N.C.; Kovtun Y.; Lai K.C.; Ab O.; Pinkas J.; Keating T.A.; Chari R.V.J.; A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody\u2013drug conjugates (ADCs). Mol Cancer Ther  2018,17(3),650-660","journal-title":"Mol Cancer Ther"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673327425240815065221","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/233277\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673327425240815065221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:14:51Z","timestamp":1743146091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/233277\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673327425240815065221","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}